Shares of Vallon Pharmaceuticals Inc. (NASDAQ:VLON) traded today at $10.20, eclipsing its 52-week high. This new high was reached on above average trading volume as 535,000 shares traded hands, while the average 30-day volume is approximately 309,000 shares.
Vallon Pharmaceuticals Inc. (NASDAQ:VLON) defies analysts with a current price ($9.65) 42.6% above its average consensus price target of $5.54.
Vallon Pharmaceuticals Inc is a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. The company develops prescription drugs for central nervous system disorders. Its product ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, and narcolepsy.
In the past 52 weeks, shares of Vallon Pharmaceuticals Inc. have traded between a low of $3.61 and a high of $10.20 and is now at $9.65, which is 167% above that low price.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer